Improving dystrophin function for treating Duchenne muscular dystrophy
Expression of dystrophins with enhanced function
This study is working on new ways to help people with Duchenne muscular dystrophy (DMD) by improving a key protein that helps muscles work better, using special tools to deliver these improvements directly to the muscles while aiming to make treatments safer and more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11048058 on NIH RePORTER |
What this research studies
This research focuses on developing enhanced versions of dystrophin, a protein crucial for muscle function, to treat Duchenne muscular dystrophy (DMD), a severe genetic disorder. The approach involves using adeno-associated viral (AAV) vectors to deliver micro-dystrophins to muscle tissues, aiming to improve their effectiveness and reduce side effects compared to existing therapies. The study also explores the use of anti-sense oligonucleotides to skip faulty parts of the dystrophin gene, potentially allowing for more efficient gene therapy. By addressing the complexities of DMD mutations, this research seeks to provide a more effective treatment option for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy, particularly those with specific genetic mutations affecting dystrophin.
Not a fit: Patients with forms of muscular dystrophy other than Duchenne muscular dystrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with Duchenne muscular dystrophy, improving their muscle function and quality of life.
How similar studies have performed: Previous studies have shown promise with similar gene therapy approaches, including the use of micro-dystrophins and anti-sense oligonucleotides, with some therapies already receiving FDA approval.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Chamberlain, Jeffrey S — University of Washington
- Study coordinator: Chamberlain, Jeffrey S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.